B — FMP rating1.
Quick AnswerDHR Q4 consensus: revenue $7.5B1, EPS $2.521. Matt Gugino guided Biotechnology to 4-5% (previous 5.5%) in the Q3 earnings call2. 7 consecutive quarters of beat1.
Content generated by AI editorial engine. Written by Stock Expert AI's research desk with AI assistance. Figures come from FMP data and the official sources cited in the article.
The median of 8 price targets is $2401, stock is $230, +4.5% vs the analyst consensus median.
B — FMP rating1.
Quick AnswerDHR Q4 consensus: revenue $7.5B1, EPS $2.521. Matt Gugino guided Biotechnology to 4-5% (previous 5.5%) in the Q3 earnings call2. 7 consecutive quarters of beat1.
Next report
Watchlist
Fy2026 Eps Guidance Raise
Danaher raised its FY2026 adjusted diluted EPS guidance to $8.57-$8.62 from $8.45-$8.60, reflecting Q3 outperformance.
Matt Gugino, CFO - Q3 FY26 Earnings Call - October 21, 20262027 Core Growth Starting Point
2027_core_growth_starting_point
Management views 4%-5% core revenue growth excluding respiratory as the right starting point for 2027.
Matt Gugino, CFO - Q3 FY26 Earnings Call - October 21, 2026Q3 Core Growth Margin
Danaher's Q3 core revenue growth excluding respiratory accelerated to 5.5% with an adjusted operating margin of nearly 30%.
Julie Sawyer Montgomery, CEO - Q3 FY26 Earnings Call - October 21, 2026Ceo Strategic Priorities
New CEO Julie Sawyer Montgomery set four strategic priorities: commercial excellence, innovation, talent, and effective capital allocation.
"As we enter this next chapter, we'll accelerate that ambition by focusing on 4 strategic priorities: commercial excellence, innovation, talent, and effective capital allocation."
- Julie Sawyer Montgomery, CEO - Q3 FY26 Earnings Call - October 21, 2026
Bioprocessing Orders
Bioprocessing orders grew mid-teens in Q3, with particular strength in upstream consumables and reagents.
Matt Gugino, CFO - Q3 FY26 Earnings Call - October 21, 2026Stock Expert AI - Methodology
Historical V1 earnings-model score (archived, Oct 23, 2026) — not the current MoonshotScore. Current MoonshotScore: DHR stock page
multi-pillar methodology. Cash Runway and Price Momentum strong. Revenue Growth weak.
How is it calculated? ->6 investor frameworks. 2 bullish (Ray Dalio, Ken Griffin), 0 bearish (none), 4 neutral (Jim Simons, Klarman, Buffett, Munger).
How is it calculated? ->Quality business, trading at fair value.
How is it calculated? ->Past Performance
"In the fourth quarter, we expect core revenue growth excluding respiratory revenue to be in the 4%-5% range."
- Matt Gugino, CFO - Q3 FY26 Earnings Call - October 21, 2026
No RPO/backlog concentration disclosed in Q3 earnings call.
Form 4 Q3 FY26: 4 transactions, net -$12.97M1.
4 transactions · 4 sales / 0 purchases = net negative flow. Not large in absolute terms against a $161.5B market cap.
Not advice - a structural framework for earnings night. Decision discipline is yours.
Market Outlook
You read it in 5 minutes. When the numbers come out on Wednesday evening - you know what you're looking at.
Data arrives at night. The framework is ready now.
Data arrives on Wednesday evening. The framework is ready on this page: Q4 EPS threshold $2.521, Biotechnology guidance 4-5%2, CapEx threshold "below $255.0M". Three anchors, three scenarios.
Comparison Stock Expert AI is free today — no credit card.
Seeking Alpha $299/yr - analyst opinions + earnings coverage TipRanks $360/yr - Smart Score (1-10) + analyst consensus + insider trades Trendspider $400/yr - AI pattern detection + automated TA + multi-timeframe alerts
Prices as of April 2026. Sources: seekingalpha.com/subscriptions - tipranks.com/pricing - trendspider.com/pricing
Stock Expert AI is free today — no credit card. Council 6-lens analysis + MoonshotScore multi-pillar + Insider tracker + Technical levels - all in one platform, for every stock.
Educational tool, not investment advice. Past performance does not guarantee future results.
Calendar
DATA GAP: Events not in the FMP /stable/calendar feed - Investor day, analyst day, product launches, regulatory dates. These require company IR page scraping or manual calendar entry.
This Danaher Corporation (DHR) Q4 FY26 earnings preview covers the analyst consensus, key catalysts, and what to watch on the earnings call.
Danaher Corporation (DHR): Consensus EPS, revenue guidance, segment growth rates, and the tone of management commentary — the full breakdown with sources is on this page.
Danaher Corporation (DHR): Figures are sourced from Financial Modeling Prep (FMP) fundamentals and consensus data plus official earnings-call transcripts; derived metrics are labeled with their source next to each figure.
Danaher Corporation (DHR): No. This page is educational research, not investment advice. It summarizes analyst consensus and company data; consult a licensed financial advisor before making any investment decision.